Open Orphan, a European-focused, rare and orphan drug consulting services platform, today announced it has signed a new strategic collaboration agreement ('the Collaboration') with Empiric Logic to build on the earlier work performed by Open Orphan and complete the build out of Open Orphan's Health Data platform, Europe's first rare disease, advocacy-led genomic database.

Europe-focussed rare and orphan drug consulting services platform provider Open Orphan has signed a new strategic collaboration agreement with Empiric Logic, it announced on Tuesday, to build on the earlier work it had performed, and complete the build out of its &lsquo;Health Data&rsquo; platform as Europe's first rare disease, advocacy-led genomic database.

The company will include Empiric's privacy-preserving and artificial intelligence-enabled software in its rare disease database Orphan drugs treat rare diseases and address unmet medical needs Open Orphan Plc (LON:ORPH) said it has taken an 'exciting step' towards the completion of it Genomic Health Data Platform following a tie-up with a firm called Empiric Logic.